Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Ultrasound contrast agent
Reexamination Certificate
2006-02-14
2006-02-14
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Ultrasound contrast agent
C424S130100, C424S145100, C435S320100, C435S810000, C530S387100, C530S387300, C530S388100, C530S388230, C530S389700
Reexamination Certificate
active
06998108
ABSTRACT:
A novel ligand (p30) for herpes virus entry mediator, HVEM, is provided. p30 is useful for modulating immune responses and in inhibiting infection by herpes virus. Methods for treating subjects with lymphoid cell disorders or those having or suspected of having a herpes virus infection, utilizing p30 of the invention, are also provided.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5969120 (1999-10-01), Fung et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 0897114 (1999-02-01), None
patent: WO 94/13808 (1994-06-01), None
patent: WO 96/34095 (1996-10-01), None
patent: WO 9703199 (1997-01-01), None
patent: WO 97/04658 (1997-02-01), None
patent: WO 97/04658 (1997-02-01), None
patent: WO 97/34911 (1997-09-01), None
patent: WO 98/03648 (1998-01-01), None
patent: WO 98/ 17313 (1998-04-01), None
patent: WO 98/18824 (1998-06-01), None
patent: WO 98/25967 (1998-06-01), None
patent: WO 98/51246 (1999-01-01), None
patent: WO 99/02563 (1999-01-01), None
patent: WO 99/11662 (1999-03-01), None
patent: WO 99/35262 (1999-07-01), None
patent: WO 99/42584 (1999-08-01), None
patent: WO 00/10591 (2000-03-01), None
patent: WO 00/14230 (2000-03-01), None
patent: WO 00/21558 (2000-04-01), None
patent: WO 00/53223 (2000-09-01), None
Vingerhoeds et al, Immunomethods 4: 259-272; 1994.
Ikuta et al, Virus Research 6(2): 101-108, 1986.
Kuby et al, 1994, Immunology, Second edition, pp. 85-96.
Harlow et al in Antibodies a Laboratory Manual, 1998, Cold Spring harbor laboratory publication, Cold Spring Harobr, NY, pp. 92-94, pp. 116-117, pp. 626-629.
Browning et al, J Immunol 1995 Jan 1;154(1):33-46.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Colman et al, 1994, A structural view of immune recognition by antibodies, pp. 33-36.
Huang et al., “Anti-idiotypic antibodies mimicking glycoprotein D of herpes simplex virus identify a cellular protein required for virus spread from cell to cell and virus-induced polykaryocytosis”,Proceedings of the National Academy of Science USA,Mar. 1996, vol. 93, pp. 1836-1840.
Montgomery et al., “Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family”,Cell,Nov. 1, 1996, vol. 87, pp. 427-436.
Harrop, et al, “Herpesvirus Entry Mediator Ligand (HVEM-L), A Novel Ligand for (HVEM/TR2, Stimulates Proliferation of T Cells and Inhibits HT29 Cell Growth,”Journal of BiologicalChemists, 1998, vol. 273, No. 42, pp. 27548-27556.
Harrop, et al, “HVEM-L, A Novel Ligand For HVEM/TR2, Stimulates NF-KB Dependent Transcription and T Cell Proliferation,”J. of Interferon and Cytokine Research,1998, vol. 18, No. 5, pp. 1079-9907.
Harrop, et al., “Antibodies to TR2 (Herpesvirus Entry Mediator), A New Member of the TNF Receptor Superfamily, Block T Cell Proliferation, Expression of Activation Markers, and Production of Cytokines,”J. of Immunology,1998, vol. 161, No. 4, pp. 1786-1794.
Kwon, et al., “A Newly Identified Member of the Tumor Necrosis factor Receptor Superfamily with a Wide Tissue Distribution and Involvement in Lymphocyte Activation,”J. of Biological Chemistry,1997, vol. 272, No. 22, pp. 14272-14276.
Mauri, et al., “Light, A New Member of the TNF Superfamily, and Lymphotoxin Alpha are Ligands for Herpesvirus Entry Mediator,”Immunity,1998, vol. 8, pp. 1074-7613.
Montgomery, et al., “Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family,”Cell,1996, vol. 87, pp. 427-436.
Puglielli, et al., “Reversal of Virus-induced Systemic Shock and Respiratory Failure by Blockade of the Lymphotoxin Pathway,”Nature Medicine,1999, vol. 5, No. 12, pp. 1078-8956.
Zhai, et al, “Light, A Novel Ligand for Lymphotoxin Beta Receptor and TR2/HVEM induces Apoptosis and Suppresses in Vivo Tumor Formation via Gene Transfer,”J. of Clinical Investigation,1998, vol. 102, No. 6, pp. 1142-1151.
Nicola, Anthony, et al., “Structure-Function Analysis of Soluble Forms of Herpes Simplex Virus Glycoprotein D,”J. of Virology,Jun. 1996, vol. 70., No. 6, pp. 3815-3822.
Nicola, A., et al., “Monoclonal Antibodies to Distinct Sites on Herpes Simplex Virus (HSV) Glycoprotein D Block HSV Binding to HVEM,”J. of Virology,(May 1998) vol. 72, No. 5, pp. 3595-3601.
Huang, et al. “Anti-idiotypic Antibodies Mimicking Glycoprotein D of Herpes Simplex Virus Identify a Cellular Protein Required for Virus Spread From Cell to Cell and Virus-induced Polykaryocytosis,”Proc. Natl. Acad. Sci. USA,(Mar. 1996) vol. 93, pp. 1836-1840.
Chan Christina
Huynh Phuong
La Jolla Institute for Allergy and Immunology
LandOfFree
Antibodies to p30 polypeptides and methods making and using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to p30 polypeptides and methods making and using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to p30 polypeptides and methods making and using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3690002